In The News,
Payer/KOL P&R Input to New Oncology Biologic Development Plan
In order to test a variety of potential TPPs with payers to define value, positioning, and clinical and economic benefits necessary to optimize P&R for a new oncology biologic – and gain payer insights on the evolving competitive landscape, including biosimilars – ADVI conducted primary research with payer informant KOLs and secondary research to augment company knowledge and develop the “right questions” and TPPs.
Interested in hearing more from us?
Receive customized email alerts from the ADVI team